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We previously showed that lumican decreases melanoma progression. The aim of the present study
was to determine the active sequence of the lumican core protein responsible for the inhibition of
melanoma cell migration. Using different recombinant and synthetic peptides derived from lumi-
can, we localized an active site in the leucine-rich repeat 9 domain of the lumican core protein.
We propose the name lumcorin (fragment of lumican core protein) for the active peptide derived
from this site. Lumcorin was able to inhibit melanoma cell migration in vitro.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lumican is an extracellular matrix (ECM) protein present in
normal adult skin as a glycoprotein with a 37 kDa core protein. It
was ﬁrst identiﬁed in the cornea, where it is expressed as a proteo-
glycan with keratan sulfate chains [1]. Lumican belongs to the
small leucine-rich proteoglycan (SLRP) family which also includes
decorin, biglycan and ﬁbromodulin [2]. A signature characteristic
for the SLRP family is the leucine-rich repeat (LRR) domains which
consists of internal tandem repeats rich in leucine. These repeats
contain the 11-amino acid hallmark motif LxxLxLxxNxI/L [3].
Lumican contains 11 LRR motifs [4]: six of them are constituted
by the exact sequence LxxLxLxxNxL and ﬁve by a close sequence.
There is a correlation between internal repeats and the ‘‘banana-
shaped” tertiary structure of the SLRP, thought to be involved in
protein–protein interactions [5]. Some LRR of SLRP have biological
activities: LRR 5 and 6 from decorin and LRR 11 from ﬁbromodulin
are involved in collagen type I binding [6,7]. Moreover, the decorin
LRR 5 shows anti-angiogenic properties [8,9]. Like decorin andchemical Societies. Published by E
, extracellular matrix; LRR,
ycan
Y. Wegrowski).
k.ﬁbromodulin, lumican contributes to collagen ﬁbrillogenesis [10].
Knock-out mice for lumican have a fragile dermis due to irregular
ﬁbrillar meshwork. In addition to its role in collagen ﬁbrillogenesis,
lumican possesses anti-tumor activity. It inhibits melanoma pro-
gression in vivo and in vitro [11–13]. In breast cancer, a low
expression of lumican correlates with poor outcome of invasive
carcinoma [14].
So far, the speciﬁc amino-acid sequence of the lumican core
protein responsible for inhibiting lumican-dependent tumor cell
migration has not been determined. The aim of the present study
was to identify the active amino-acid sequence of lumican. We
demonstrated that a peptide from the LRR 9 domain of human
lumican inhibits melanoma cell migration. We propose the name
of lumcorin (fragment of lumican core protein) for this anti-migra-
tory peptide.
2. Materials and methods
2.1. Peptide synthesis
The peptides corresponding to LRR motif lumican sequences
LQHNRLKEDAVS (peptide 5), VSLLTLYLDNNKISNIP (peptide 7),
NALQYLRLSHNELADSG (peptide 8), SSLVELDLSYNKLKNIP (peptide
9, lumcorin), SYSKIKHLRLDGNRISE (peptide 11) and the scrambled
peptide LPSVSILEKLYNNLSKD (peptide 9 SCR), were obtained fromlsevier B.V. All rights reserved.
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Fig. 1. Reversible inhibition of melanoma cell migration by lumican core protein.
Recombinant lumican core protein inhibits melanoma cell migration. Cells (5  104)
were seeded on Transwell membranes coated with lumican (10 lg) or equimolar
amount of BSA (controls) and incubated for 24 h at 37 C. The cells were stained
with crystal violet and were counted in ﬁve random ﬁelds. Insert: A375 cells were
pre-incubated on plastic or on lumican coating for 24 h. Cells were then detached
and seeded on Transwell membranes without any coating. The percentage of
migrated cells was quantiﬁed after 24 h of migration. , signiﬁcantly different from
the control (**P < 0.01, ***P < 0.001).
3028 C. Zeltz et al. / FEBS Letters 583 (2009) 3027–3032GenScript Corporation (Piscataway, NJ, USA). Peptides were dis-
solved in 18 mM acetic acid.
2.2. Cell culture
Human melanoma cell lines A375 (CRL-1619), HT144 (HTB-
63TM) and murine melanoma B16F1 (CRL-6323) were obtained from
the American Type Culture Collection (ATCC) and cultured as rec-
ommended by supplier.
2.3. Cell viability and apoptosis assay
For measuring cell viability, cells (15  103 per well) were pla-
ted into 96-well plates. At the 2nd day, peptide 9 or 9 SCR
(100 lM) were added into the wells. The toxicity of the peptides
was then measured using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT).
For apoptosis assay, cell nuclei were stained with Hoechst
33342 (1 lg/ml) 24 h after incubation of the cells with peptide 9
or 9 SCR. Doxorubicin (2 lM), a pro-apoptotic drug, was used as
positive control [15]. Nuclear morphology (nuclear fragmentation)
was visualized with an inverted ﬂuorescence microscope (Axiovert
200M, Zeiss, Oberkoken, Germany).
2.4. Expression and puriﬁcation of recombinant lumican core protein
and its fragments
Recombinant human lumican core protein (37 kDa) was pro-
duced as previously described [12]. Recombinant lumican frag-
ment, L1–9 (Gly#15-Leu#266), was obtained after digestion of
the human lumican cDNA by KpnI and HindIII and cloned into
the multiple cloning site of PQE-30 vector (Qiagen, Courtaboeuf,
France).
L1–6 fragment (Gly#15-Ser#206) was obtained using 50-gag-
ctcggtaccagtggccagtactat-30 forward and 50-tggtgaaagcttagagacagg
gagaccaga-30 reverse primers. The obtained cDNA fragment was
cloned into the KpnI/HindIII site of PQE-30. The sequence of both
constructs was checked by sequencing. The recombinant lumican
and fragments were puriﬁed on Ni-NTA resin superﬂow afﬁnity
chromatography via their 6 Histidine tag as already described
[12]. Lumican core protein and fragments were dissolved in
18 mM acetic acid.
2.5. Western immunoblotting
The rabbit polyclonal antibody raised against the synthetic
human lumican peptide (17 amino acids: YLDNNKISNIPDEYFKR),
used in our previous works [11], does not recognize L1–6 frag-
ment. Immunoreactive serum raised against human lumican
was prepared after three intra-dermal injections of human
lumican core protein every 3 weeks in a rabbit. First injection
contained complete Freund’s adjuvant and the boosters incom-
plete Freund’s adjuvant. The serum was puriﬁed through
DEAE-Afﬁ-gel Blue gel column (Bio-Rad Laboratories, Marnes-
la-Coquette, France). The speciﬁcity of the puriﬁed serum was
checked by Western immunoblotting on total protein extracts
from bovine cornea and on human recombinant lumican core
protein. The immunoreactivity efﬁciency of this immunopuriﬁed
serum was compared to the rabbit polyclonal antibody raised
against the synthetic human lumican peptide used in our previ-
ous works.
Following electrophoresis, recombinant human lumican core
protein and fragments were transferred from the polyacrylamide
gels to nitrocellulose by electroblotting. The membranes were
soaked in TBS-T solution (0.005% Tween 20, 20 mM Tris and
140 mM NaCl, pH 7.6) containing 5% bovine serum albumin(BSA) for 2 h. After washing, the membranes were incubated with
the immunopuriﬁed serum raised against the recombinant human
lumican at a ﬁnal dilution of 1:500 overnight at 4 C with constant
agitation. The membranes were washed with TBS-T and probed
with 1:10 000 dilution of a goat anti-rabbit secondary antibody
conjugated to horseradish peroxidase in a solution of 1% BSA in
TBS-T for 45 min at room temperature. After washing in TBS-T,
the complexes were revealed by the AmershamTM ECL Chemilumi-
nescence Detection kit (GE Healthcare, Buckinghamshire, UK).
2.6. Cell migration assay
Cell migration stimulated by serum gradient were performed
in Transwell chambers (Greiner Bio-one, Courtaboeuf, France)
as previously described [13]. Transwell chambers were coated
either with 10 lg of recombinant human lumican core protein
or equimolar amounts of BSA or 10 lg of type I collagen. Cells
(5  104) in 100 lL medium supplemented with 0.2% BSA were
placed into the upper chamber of the Transwell device. Six hun-
dred and ﬁfty microliters of medium containing 2% BSA and 10%
FBS were placed into the lower chamber. To investigate the effect
of the different synthetic peptides, cells were pre-incubated for
2 h with peptides 5, 7, 8, 9, 11 or 9 SCR (100 lM) before being
added to the upper chamber of the Transwell. After 24 h of incu-
bation, the cells were ﬁxed with methanol and stained with crys-
tal violet. The cells remaining in the upper chamber were
removed by cotton swab. Migrated cells, on the lower side of
the ﬁlter, were counted in ﬁve random ﬁelds using the Cell Coun-
ter plugin of the ImageJ software (Rasband, W.S., ImageJ, U.S. Na-
tional Institutes of Health, Bethesda, Maryland, USA, http://
rsb.info.nih.gov/ij/, 1997–2008).
2.7. Homology modeling of lumican
The 3D structure of lumican was obtained using Swiss-Pdb
Viewer software [16] from the crystal structure of decorin and
biglycan (PDB # 1xku and PDB # 2ft3) as template.
C. Zeltz et al. / FEBS Letters 583 (2009) 3027–3032 30292.8. Statistical analysis
Results were expressed as the means ± S.D. of three replicates
and are representative of three independent experiments. Statisti-
cal signiﬁcance was assessed, by the comparison of each group to
the control group, by unpaired Student’s test, with P < 0.05 being
considered as signiﬁcant. Analysis of variance (ANOVA) was per-
formed using the Fisher’s test.3. Results
3.1. The human lumican core protein inhibits melanoma cell migration
in a reversible manner
To study the effect of the lumican core protein on melanoma
cell migration, we selected three melanoma cell lines: Human mel-
anoma A375 and HT144 cells and murine melanoma B16F1 cells.
Lumican signiﬁcantly inhibited the three melanoma cell line
migration in Transwell devices (Fig. 1). The inhibitory effect of
lumican was reversible: the migration of A375 cells, pre-incubated
for 24 h on a lumican-coated plate, was not affected when these
cells were no longer in contact with the lumican core protein
(Fig. 1, insert).1
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Fig. 2. Identiﬁcation of an active domain within the lumican core protein able to inhibit
lumican core protein and its fragments used for this study. The LxxLxLxxNxL motifs are r
(B) Western immunoblotting detection of the lumican core protein and the L1–6 and L1–
(C) Effect of the recombinant lumican fragments on A375 melanoma cell migration.
membranes coated with BSA (control), lumican or lumican fragments. Analysis of varian
were signiﬁcantly different for one group to another one (F356 ¼ 9:56, P < 0.001). , signiﬁc3.2. Identiﬁcation of an active fragment within lumican core protein
able to inhibit melanoma cell migration
In order to identify the sequence responsible for the inhibition
of tumor cell migration within the lumican core protein, two re-
combinant fragments of lumican: L1–9 (30.5 kDa, containing the
LRR 1–9) and L1–6 (23.9 kDa, containing the LRR 1–6) were pro-
duced (Fig. 2A and B). Transwell membranes were coated with
these fragments, or the complete lumican core protein, in equimo-
lar amounts. As shown in Fig. 2C, L1–9 fragment inhibited A375
cell migration by 60% (P < 0.01), whereas L1–6 fragment had no ef-
fect, indicating that an active site for migration inhibition was
present within the LRR 7–9 domain of lumican.
3.3. The LRR 9 motif inhibits melanoma cell migration
Lumican, decorin, biglycan and ﬁbromodulin belong to SLRP
family and have similar biological activities, particularly anti-tu-
mor properties [17,18]. A sequence with an important function
such as the inhibition of cell migration, should be conserved
among the SLRPs. Thus, we aligned the amino acid sequences of
these four SLRPs and focused on the LRR 7–9 region (Fig. 3A).
The sequence alignment showed 54% (6/11) of conserved amino
acids in the LRR 9 motif, whereas 27% only (3/11) were conserved2 3 4 5 6 7 8 9 10 11
2 3 4 5 6 7 8 9
2 3 4 5 6
COOH
COOH
COOH
melanoma cell migration. (A) Schematic representation of the human recombinant
epresented by the numbered black (consensus) and grey (partial consensus) boxes.
9 fragments. The position migration of size markers are depicted on the left margin.
The migration assay was processed as described in Section 2, using Transwell
ce (ANOVA) performed with the Fisher’s test conﬁrmed that the four groups of data
antly different from the control by unpaired Student’s test (**P < 0.01, ***P < 0.001).
3030 C. Zeltz et al. / FEBS Letters 583 (2009) 3027–3032in both LRR 7 and 8 motifs. Therefore, the LRR 9 motif was consid-
ered as a good candidate to lead the anti-migratory effects of the
complete lumican core protein. Accordingly, a synthetic peptide
(peptide 9), corresponding to the LRR 9 motif with its ﬂanking se-
quences was studied for its anti-migratory properties. As controls,
we also used two other peptides (peptide 5 and peptide 11) chosen
outside the active LRR 7–9 fragment and corresponding to the LRR
5 and LRR 11 motifs of human lumican, respectively. The localiza-
tion and amino-acid sequence of these peptides on the lumican
core protein are presented in Fig. 3B. Homology modeling showed
that the amino acid residues of peptides 8, 9 and 11 were located in
the concave side of lumican, whereas most of residues from pep-
tide 5 were in the convex side (Fig. 3C).
The three synthetic peptides (5, 9 and 11) were tested at a
100 lM concentration on A375 cell migration in Transwell de-
vices. As shown in Fig. 4A, peptide 9, but not peptides 5 or 11, sig-
niﬁcantly decreased A375 cell migration compared to the control,
with a dose-dependent response (correlation coefﬁcient r = 0.994,
P < 0.001). Thus, a concentration of 100 lM for the peptide 9 was
chosen for the following experiments. None of the studied peptides
showed any cytotoxic or pro-apoptotic effects, as appreciated by
the MTT test or Hoechst staining, respectively (data not shown).RLPSGLPVSLLTLYLDNNKISNIPDEYFKRFNALQY
KVPDGLPSALEQLYMEHNNVYTVPDSYFRGAPKLLY
SIPQGLPPSLTELHLDGNKISRVDAASLKGLNNLAKL
GIPKDLPETLNELHLDHNKIQAIELEDLLRYSKLYRL
  *  **  *  *    *               *   
Lum
Fib
Dec
Big
LRR 7 β-strand LRR
Amino acids 
 similarity (%) % 72
1 2 3 4 5 6
LQHNRLKEDAV
peptide 5
A
B
C
NALQYLRL
pep
Fig. 3. Lumican amino acid sequence analysis. (A) Alignment of the partial protein sequ
biglycan (Big)) including the LRR 7–9 domains. LRR consensus sequences are indicated by
basic amino acids, red: small (small and hydrophobic) amino acids, green: remaining am
LRR consensus motif is indicated below the sequences. The analysis was done using
www.ebi.ac.uk). (B) Sequences and localization of the different synthetic peptides used
peptide. (C) View of the concave side of lumican molecule, modeled after decorin and big
8, 9 and 11 residues are shaded in pink, yellow, red and blue respectively.Migration assays with other melanoma cell lines (Fig. 4B) showed
that peptide 9 signiﬁcantly inhibited the migration of A375, HT144
and B16F1 cells (60%, P < 0.001; 30%, P < 0.05; 30%, P < 0.05,
respectively), whereas the corresponding scramble peptide had
no effect on cell migration.
Altogether, these results indicate that the LRR 9 motif sequence
of lumican is responsible for the inhibition of the melanoma cell
migration. We propose the name of lumcorin (fragment of lumican
core protein) for this peptide.
Complementary experiments showed that lumcorin does not
inﬂuence cell adhesion on lumican (Supplementary material,
Fig. 1) or type I collagen (Supplementary material, Fig. 2). On the
other hand, it was able to inhibit cell migration through colla-
gen-coated Transwell membranes (Supplementary material,
Fig. 3).
To address the question of the function of LRR 7 and LRR 8 do-
mains, we performed additional migration assays comparing lum-
corin effect to LRR 7-derived peptide (peptide 7) and LRR 8-derived
peptide (peptide 8). Results are shown in Supplementary material,
Fig. 4. Peptide 7 exhibited high hydrophobic properties and
aggregated melanoma cells in a non speciﬁc way. Therefore, it
was not suitable for our experiments. Peptide 8 did not decreaseLRLSHNELADSGIPGNSFNVSSLVELDLSYNKLKNIP
VRLSHNSLTNNGLASNTFNSSSLLELDLSYNQLQKIP
GLSFNSISAVDNGSLAN-TPHLRELHLDNNKLTRVP
GLGHNQIRMIENGSLSF-LPTLRELHLDNNKLARVP
 *  *                * ** *  * *   *
 8 β-strand LRR 9 β-strand
% 72 54 %
7 8 9 10 11
SSLVELDLSYNKLKNIP
SYSKIKHLRLDGNRISES
peptide 9
peptide 11
SHNELADSG
tide 8
ences of four human SLRPs (lumican (Lum), ﬁbromodulin (Fib), decorin (Dec) and
stars and identical amino acids by black letters (blue: acidic amino acids, magenta:
ino acids). The amino acid sequence similarity (%) between the four SLRPs for each
ClustalW2 software accessible at the European Bioinformatics Institute (http://
in this study. The amino acid sequence and its location are represented for each
lycan crystal structures (PDB # 1xku and PDB # 2ft3). Part of peptide 5 and peptides
020
40
60
80
100
%
 o
f m
ig
ra
te
d 
ce
lls
 / 
Co
nt
ro
l
Control       9
(100 µM)
     9
(10 µM)
    9
(1 µM)
5 11
peptides
***
*
0
20
40
60
80
100
120
%
 o
f m
ig
ra
te
d 
ce
lls
 / 
Co
nt
ro
l
A375 B16F1 HT144
Melanoma cell lines
*** * *
Control
peptide 9
peptide 9 SCR
A
B
Fig. 4. LRR 9 motif inhibits melanoma cell migration. (A) Effect of the three
synthetic peptides (5, 9 and 11) on A375 melanoma cell migration. Cells (5  104
per dish) were pre-incubated for 2 h at 37 C in suspension with either the peptide 5
or 11 at concentrations 0 (control) or 100 lM or the peptide 9 at a concentration of
0 (control), 1, 10 or 100 lM (grey columns) and then seeded for 24 h at 37 C on
BSA-coated Transwell membranes. (B) Effect of peptide 9 (100 lM) on the
migration of different melanoma cell lines. Cells were incubated with either the
peptide 9 or peptide 9 scramble (9 SCR) (100 lM) or without peptide (control)
before being seeded on Transwell membranes. The migration was measured as
described in Fig. 1. ANOVA performed with the Fisher’s test conﬁrmed that the
groups of data were signiﬁcantly different for one group to another one (Fig. 4A,
F584 ¼ 15:93, P < 0.001; Fig. 4B, F242 ¼ 9:1, P < 0.001, F215 ¼ 6:76, P < 0.01; F215 ¼ 39:8,
P < 0.001 for A375, B16F1 and HT144, respectively). , signiﬁcantly different from
the control by unpaired Student’s test (*P < 0.05, **P < 0.01, ***P < 0.001).
C. Zeltz et al. / FEBS Letters 583 (2009) 3027–3032 3031signiﬁcantly B16F1 cell migration compared to control. A375 cell
migration was inhibited by peptide 8, but to a lesser extent than
lumcorin.
4. Discussion
Tumor cell migration is an important process during melanoma
progression, leading to invasion and metastasis. ECM macromole-
cules may be involved in the control of this process [19]. Lumican,
a component of the ECM, may be considered as an anti-tumor mol-
ecule, since it is able to decrease melanoma progression in vivo
[12]. Lumican is located in the dermis and in the peritumoral stro-
ma of malignant melanoma, suggesting a defense mechanism
against melanoma progression [11]. Here, we demonstrate that
the migration inhibition is due to a speciﬁc sequence of the lumi-
can core protein located in the LRR 9 domain. We propose to give it
the name of lumcorin (fragment of lumican core protein).
In SLRPs, protein binding sites are located in the concave side of
the molecule. This side is formed by parallel b-sheets, formed by
the LRR motif sequences LxxLxLxxNxL [5,20]. For this reason, we
focused on LRR motifs to determine the active site of lumican
responsible for migration inhibition. The alignment results of the
four main SLRPs suggested the LRR 9 motif as a potential target.
Lumcorin affected cell migration only without any alteration of cell
adhesion on lumican or type I collagen substrata (Supplementary
material, Figs. 1 and 2). The fact that lumcorin did not competewith the lumican protein in the adhesion assays, indicates the
presence of distinct site(s) in lumican for cell adhesion and cell
migration.
Collagen is the major component of the extracellular matrix. As
lumican is known to interact with type I collagen [10], an interfer-
ence could occur on the inhibitory effect of lumican. Here, we ob-
served that lumcorin inhibited the migration of melanoma cell,
through collagen-coated Transwell membranes (Supplementary
material, Fig. 3), showing that the presence of collagen does not
jeopardize the inhibitory effect of lumcorin on cell migration. We
previously showed that the presence of type I collagen did not af-
fect the remodeling effect of lumican core protein on melanoma
cell cytoskeleton [21].
Lumcorin displayed different migration inhibitory efﬁciencies,
as compared to lumican, depending on the cell line. Particularly,
it decreased the migration of B16F1 and HT144 cells by 30% only
whereas lumican core protein inhibited the migration of these cells
by about 60%. This might mean that other lumican domains, espe-
cially LRR 7 and LRR 8 might be involved in the inhibition of cell
migration. Results that we obtained with peptide 8, however, did
not conﬁrm this hypothesis, at least for B16F1 cells (Supplemen-
tary material, Fig. 4). We cannot exclude an effect of peptide 7
since we were not able to test it in the migration assays, due to
its highly hydrophobic properties. Another explanation could be
that adhesion receptor expression might be different between
the three cell lines. We observed that the adhesion of B16F1 cells
on lumican was three times higher compared to A375 cells (Sup-
plementary material, Fig. 1). We previously showed that adhesion
of melanoma cells to lumican may impair cell migration [13]. In
contrast, A375 cells could have more receptors for lumcorin than
B16F1 and HT144 cells. Further studies will be necessary to test
this hypothesis.
Tumor progression could also be controlled by induction of
apoptosis and lumican has been reported to facilitate the induction
of the pro-apoptotic receptor Fas [22]. In our model, the inhibition
of melanoma migration by lumican was not due to a pro-apoptotic
effect. On the contrary, a rapid rearrangement of actin ﬁlament
organization was observed when melanoma cells were grown on
lumican [23]. Previous data from our laboratory suggest that this
interaction could induce a reorganization of focal adhesions, lead-
ing to an immobilization of melanoma cells [21]. This could con-
tribute to slow-down melanoma progression.
Decorin and biglycan, two other members of the SLRP family,
were also described as anti-tumor molecules. We suggest that
these SLRPs might have similar anti-migratory properties through
their own LRR 9 motifs. Particularly, it could be interesting to focus
on the ﬁbromodulin LRR 9, which differs from lumcorin by four
amino acids only.
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